NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Announcement: “New Publication: Bulletin MADRAC - August 2016”

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive
 

MADRAC Bulletin - August 2016

Annual Report for 2015
   ▪ Spontaneous Adverse Drug Reactions (ADRs) including Adverse Events Following Immunisation (AEFIs) Reported in Malaysia
Regulatory Matters
   ▪ Bisphosphonates: Risk of osteonecrosis of the external auditory canal.
   ▪ Minyak Cajeput (Melaleuca leucodendran): Risk of glottal spasm and bronchospasm.
   ▪ Glivec (imatinib) and Tasigna (nilotinib): Risk of Hepatitis B Virus reactivation.
   ▪ Adempas (riociguat): New contraindication for patients with pulmonary hypertension associated  with idiopathic interstitial pneumonia.
What’s New?
▪ Consumer Side Effect Reporting Form (ConSERF)

 



 
 
  DOWNLOAD PDF



  MORE MADRAC BULLETIN

 

 

 

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Thursday 10 October 2024, 15:18:19.

Search

Main Menu English